Navigation Links
INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale
Date:10/30/2009

HONOLULU - October 29, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today. The primary objective of this study was to assess the change from baseline on the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) in patients ages 6 to 12 with a primary diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) with the presence of oppositional symptoms at baseline. INTUNIV met the primary objective demonstrating significant efficacy in reducing symptoms as measured by the oppositional subscale. Some of the symptoms measured by this scale include deliberately doing things that annoy others, refusing to comply with adults' requests, and being touchy or easily annoyed by others.

According to the Centers for Disease Control and Prevention (CDC), approximately 7.8 percent of all US school-aged children have been diagnosed with ADHD at some point in their lives. ADHD is a complex neurobehavioral disorder, which includes symptoms and behaviors such as inattentiveness, running around or climbing excessively, and being excitable or impulsive, many of which can be disruptive.

"The disruptive nature of ADHD can impact social and academic settings for those patients diagnosed with the disorder," said F. Randy Sallee, MD, PhD, Professor of Psychiatry at the University of Cincinnati and Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. "This study showed that INTUNIV is an effective option for treating a range of ADHD symptoms."

INTUNIV, a once-daily formulation of guanfacine, was approved by the US Food and Drug Administration (FDA) on September 2, 2009 as the first selective alpha-2A agonist for the treatment of ADHD. Although the mechanism of action is not known, guanfacine, the active ingredient in INTUNIV, is thought to selectively stimulate alpha-2A adrenoreceptors in the prefrontal cortex. Stimulation of the postsynaptic alpha-2A receptors is thought to strengthen working memory, reduce susceptibility to distraction, improve attention regulation, improve behavioral inhibition, and enhance impulse control.

Once-daily INTUNIV is expected to be available in US pharmacies in November and will come in four dosage strengths (1 mg, 2 mg, 3 mg, and 4 mg). INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

INTUNIV Demonstrated Significant Symptom Reduction in Patients Diagnosed with ADHD and the Presence of Oppositional Symptoms

This randomized, placebo-controlled, flexible-dose study was conducted in 214 patients ages 6 to 12 over a nine-week period. INTUNIV demonstrated significant ADHD symptom improvement in the primary and secondary measures as demonstrated on the Oppositional Subscale of the CPRS-R:L and the ADHD Rating Scale-IV (ADHD-RS-IV), respectively. The CPRS-R:L is a comprehensive scale that uses parent observer and self-report ratings to help assess ADHD symptoms and behaviors in children. At the study's end, patients taking INTUNIV showed significant symptom reduction as compared to patients taking placebo (-10.9 versus -6.8; effect size 0.59; P<.001) when assessed using the oppositional subscale of the CPRS-R:L. The ADHD-RS-IV scale assesses hyperactive, impulsive, and inattentive ADHD symptoms. ADHD-RS-IV mean change from baseline for INTUNIV versus placebo was -23.8 versus -11.5; effect size 0.92; P<.001. In this study, most treatment-emergent adverse events were mild to moderate. The most commonly reported treatment-emergent adverse events in patients taking INTUNIV (greater than or equal to 10 percent) were somnolence, headache, sedation, upper abdominal pain, and fatigue.

Dr Sallee added, "The data presented today provide additional support for the safety and efficacy profile of INTUNIV. The trial's flexible dose design gives clinicians a better look at how this medication may be used in clinical practice once it becomes available in November."


'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Shires INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
2. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
3. Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
4. Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products
5. New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
6. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
7. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
8. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
9. How embryonic stem cells develop into tissue-specific cells demonstrated
10. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
11. Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... ... February 14, 2016 , ... Many eating ... professionals near their residence. The nature of the illnesses requires ongoing supervision, therapy ... time allotted at work to make traditional appointments. These people struggle to maintain ...
(Date:2/13/2016)... ... February 13, 2016 , ... Good news for retinal patients ... area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging technology used to ... diabetic retinopathy, and other vascular conditions. , In just a few seconds, OCT ...
(Date:2/13/2016)... Angeles, California (PRWEB) , ... February 13, 2016 , ... ... help landing a date for the big day. A great outfit, flawless hair, and ... ashtray, they might as well resign themselves to a night at home with Rover. ...
(Date:2/13/2016)... ... ... individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased their ... delved into this niche allowing those giving up their beloved pasta a chance to ... of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio that ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ) ... will ring the Nasdaq Closing Bell at the Nasdaq ... at 4:00 p.m. ET on Tuesday, February 16, ... Adrian Adams , will perform the honorary bell ... p.m. ET.  A live webcast will be available at: ...
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... research report titled Chronic Inflammation Global Clinical Trials ... snapshot of the global clinical trials landscape along ... trials by Region, Country (G7 & E7), Trial ... status and reviews top companies involved and enlists ...
(Date:2/11/2016)... Laboratory glassware and plasticware include ... may range from microscope slides to large storage boxes ... borosilicate glass because of its low weight and resistance ... started gaining popularity over the past decade when it ... with plastic in several applications due to its resistance ...
Breaking Medicine Technology: